Literature DB >> 14726859

Subcutaneous panniculitic T-cell lymphoma in children: response to combination therapy with cyclosporine and chemotherapy.

Ayelet Shani-Adir1, Anne W Lucky, Julie Prendiville, Sharon Murphy, Murray Passo, Frederick S Huang, Amy S Paller.   

Abstract

We describe 2 adolescent boys with facial swelling and/or subcutaneous nodules and fever. Extensive evaluation, including several biopsy specimens, led to a diagnosis of subcutaneous panniculitic T-cell lymphoma, an entity rarely seen in children. Both patients were treated with oral cyclosporine in an effort to suppress the cytokine release from T-cells that has been thought to induce the hemophagocytic syndrome. The patients responded dramatically to cyclosporine treatment with defervescence of the fever and reduction in number and size of the subcutaneous nodules. Subsequent therapy with multidrug chemotherapy achieved complete remission in the first patient. This report suggests the value of cyclosporine as a first-line agent coupled with chemotherapy in the treatment of patients with subcutaneous panniculitic T-cell lymphoma. A clinicopathologic review of 8 described pediatric cases of subcutaneous panniculitic T-cell lymphoma is also presented.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14726859     DOI: 10.1016/s0190-9622(03)00746-1

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  2 in total

1.  Hemophagocytic Lymphohistiocytosis in Cutaneous T-Cell Lymphoma.

Authors:  Dylan E Lee; M Estela Martinez-Escala; Linda M Serrano; Xiaolong A Zhou; Jason B Kaplan; Barbara Pro; Jaehyuk Choi; Joan Guitart
Journal:  JAMA Dermatol       Date:  2018-07-01       Impact factor: 10.282

2.  Cyclosporine A as a Primary Treatment for Panniculitis-like T Cell Lymphoma: A Case with a Long-Term Remission.

Authors:  Won Sup Lee; Ji-Hyen Hwang; Moon Jin Kim; Se-Il Go; Anna Lee; Haa-Na Song; Min Jeong Lee; Myung Hee Kang; Hoon-Gu Kim; Jeong-Hee Lee
Journal:  Cancer Res Treat       Date:  2014-07-15       Impact factor: 4.679

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.